Leerink Partners Starts Sensei Biotherapeutics (SNSE) at Outperform
Leerink Partners analyst Andrew Berens initiates coverage on Sensei Biotherapeutics (NASDAQ: SNSE) with a Outperform rating and a price target of $50.00.
The analyst comments "We are initiating coverage on SNSE with a $50/sh PT and OP rating. • SNSE acquired Faeth Therapeutics and is developing PIKTOR, a combination of serabelisib (PI3Kα inhibitor) and sapanisertib (mTORC1/2 inhibitor) to target the PI3K/AKT/mTOR (PAMT) pathway with a multi-node approach. • The efficacy of a multi-node approach over a single-node approach is validated by CELC’s (OP) gedatolisib (geda) in the VIKTORIA-1 trial. • PIKTOR is differentiated through its selective PI3Kα inhibition (vs. pan-PI3K), oral administration, and dosing strategy. Early data suggest low rates of hyperglycemia and stomatitis. • Ongoing Ph 2 trial in endometrial cancer will provide proof-of-concept for PIKTOR safety and broader applicability throughout oncology. Ph 2 data in endometrial expected by YE26."
For an analyst ratings summary and ratings history on Sensei Biotherapeutics click here. For more ratings news on Sensei Biotherapeutics click here.
Shares of Sensei Biotherapeutics closed at $30.49 yesterday.